Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NLY02
- Development stage
- Unknown
- Lead developer
- Neuraly
- Modality
- Peptides
- Administration
- Oral
01
Overview
NLY02 is a long-acting peptide agonist of the glucagon-like peptide-1 receptor (GLP-1R) developed by D&D Pharmatech and its subsidiary Neuraly. Designed for the treatment of metabolic disorders such as obesity, NLY02 mimics the action of the endogenous GLP-1 hormone to stimulate insulin secretion, inhibit glucagon release, and promote satiety. While its sibling candidate NLY01 is primarily focused on neurodegenerative conditions like Parkinson's disease, NLY02 is specifically optimized for metabolic indications. The compound has entered Phase 1 clinical development to evaluate its safety, tolerability, and pharmacokinetic profile in human subjects.
02
Targets
RIPK2 (Receptor-interacting protein serine/threonine kinase 2)
Beyond the preview
Go deeper on NLY02.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NLY02.